GSK acquires global rights to multiple myeloma asset, Wickes on track for 10pc jump in FY profits

GSK said it will pay up to $750 million to acquire full global rights to a trispecific T-cell engager for multiple myeloma from Chimagen Biosciences. The deal includes an upfront payment plus development and commercial milestones, and GSK expects the programme to enter Phase I trials in 2027. Separately, DIY retailer Wickes reported a 1.1% rise in earnings to £27.6 million for the six months ended 27 June, with like-for-like sales up 0.7%, and said it is on track for a 10% jump in adjusted annual profits despite an uncertain consumer environment. The round-up also notes Red Sea island seizures by Yemen’s Houthis, calls to slow UK gilt sales, and UK energy import dependence, alongside other corporate and political items.